lansoprazole has been researched along with Colicky Pain in 15 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 9.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "A double-blind, multicentre study was undertaken in 296 patients with endoscopically proven duodenal ulcer to compare the efficacy and safety of lansoprazole 15, 30 or 60 mg with placebo." | 9.08 | A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group. ( Avner, DL; Dorsch, ER; Greski-Rose, PA; Jennings, DE, 1995) |
| " A total of 329 adult outpatients fulfilling the Rome III criteria for functional dyspepsia were randomly allocated to receive either lansoprazole 30 mg once daily (n = 166) or mosapride 5 mg thrice daily (n = 163) for 2 weeks." | 5.15 | Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? ( Hsu, WL; Hsu, YC; Lin, HJ; Lin, JT; Liou, JM; Wang, HP; Wu, HT; Wu, MS; Yang, TH, 2011) |
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 5.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "A double-blind, multicentre study was undertaken in 296 patients with endoscopically proven duodenal ulcer to compare the efficacy and safety of lansoprazole 15, 30 or 60 mg with placebo." | 5.08 | A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group. ( Avner, DL; Dorsch, ER; Greski-Rose, PA; Jennings, DE, 1995) |
| "Patients with active HP infection and peptic ulcer, a history of peptic ulcer, or nonulcer dyspepsia were randomized to either lansoprazole 30 mg b." | 5.08 | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. ( Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM, 1997) |
| "Although bismuth was both the first drug shown to alter the natural history of peptic ulcer disease and also a constituent of the first very effective eradication regimens, it has been excluded from the newer regimens, despite its safety and low cost, in favour of two antibiotics." | 5.08 | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. ( Scott, BB, 1998) |
| "Lansoprazole can cause MC." | 2.47 | Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. ( Attilia, F; Capurso, G; Colarossi, C; Delle Fave, G; Di Giulio, E; Marignani, M; Milione, M; Zampaletta, C, 2011) |
| "To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on pharmacological aspects." | 2.43 | Treatment of gastroesophageal reflux disease. ( Camargos, PA; Guimarães, EV; Marguet, C, 2006) |
| "Cough was significantly less severe in NEE adolescents than in younger children." | 1.33 | Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. ( Amer, F; Chiu, YL; Gupta, SK; Hassall, E; Heyman, MB, 2006) |
| "To estimate the rates of common adverse events in patients treated with the proton pump inhibitors omeprazole, lansoprazole and pantoprazole in general practice in England." | 1.31 | The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. ( Dunn, NR; Freemantle, S; Martin, RM; Shakir, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kajihara, Y | 1 |
| Kovacs, TO | 1 |
| Freston, JW | 1 |
| Haber, MM | 1 |
| Hunt, B | 1 |
| Atkinson, S | 1 |
| Peura, DA | 1 |
| Hsu, YC | 1 |
| Liou, JM | 1 |
| Yang, TH | 1 |
| Hsu, WL | 1 |
| Lin, HJ | 1 |
| Wu, HT | 1 |
| Lin, JT | 1 |
| Wang, HP | 1 |
| Wu, MS | 1 |
| Capurso, G | 1 |
| Marignani, M | 1 |
| Attilia, F | 1 |
| Milione, M | 1 |
| Colarossi, C | 1 |
| Zampaletta, C | 1 |
| Di Giulio, E | 1 |
| Delle Fave, G | 1 |
| Tiesmeier, J | 1 |
| Hinner, H | 1 |
| Kraus, J | 1 |
| Schuppert, F | 1 |
| Suzuki, H | 1 |
| Masaoka, T | 1 |
| Sakai, G | 1 |
| Ishii, H | 1 |
| Hibi, T | 1 |
| Gupta, SK | 1 |
| Hassall, E | 1 |
| Chiu, YL | 1 |
| Amer, F | 1 |
| Heyman, MB | 1 |
| Guimarães, EV | 1 |
| Marguet, C | 1 |
| Camargos, PA | 1 |
| Perez, ME | 1 |
| Youssef, NN | 1 |
| Bender, E | 1 |
| Schmidt, SP | 1 |
| Avner, DL | 1 |
| Dorsch, ER | 1 |
| Jennings, DE | 1 |
| Greski-Rose, PA | 1 |
| Chey, WD | 1 |
| Fisher, L | 1 |
| Elta, GH | 1 |
| Barnett, JL | 1 |
| Nostrant, T | 1 |
| DelValle, J | 1 |
| Hasler, WL | 1 |
| Scheiman, JM | 1 |
| Scott, BB | 1 |
| Richter, JE | 1 |
| Campbell, DR | 1 |
| Kahrilas, PJ | 1 |
| Huang, B | 1 |
| Fludas, C | 1 |
| Martin, RM | 1 |
| Dunn, NR | 1 |
| Freemantle, S | 1 |
| Shakir, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753] | Phase 4 | 143 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome[NCT00663897] | Phase 4 | 329 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lansoprazole and Colicky Pain
| Article | Year |
|---|---|
Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Aged; Aged, 80 and over; Anti-Ulcer Agents; | 2011 |
Treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Anti-Ulcer Agents; Barre | 2006 |
Dyspepsia in childhood and adolescence: insights and treatment considerations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Acetates; Acupuncture Therapy; Adolescent; | 2007 |
6 trials available for lansoprazole and Colicky Pain
| Article | Year |
|---|---|
Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Diarrhea; D | 2009 |
Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Anti-Ulcer Agents; Benzamides; Dyspe | 2011 |
A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Ulcer Agents; Double-Blin | 1995 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1997 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; | 1998 |
Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Antacids; A | 2000 |
6 other studies available for lansoprazole and Colicky Pain
| Article | Year |
|---|---|
An elderly woman with progressive odynophagia, epigastralgia and nausea.
Topics: Abdominal Pain; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Endoscopy, Digesti | 2018 |
[Chronic upper abdominal pain without improvement after using proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Ulcer Agents; Azathioprine; Duodenal U | 2004 |
Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2005 |
Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Anorexia; Anti-Ulcer Agents; Ch | 2006 |
Extraintestinal heterotopic gastric tissue simulating acute appendicitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Acute Disease; Aged; Appendicitis; Choristo | 2008 |
The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Adverse Drug Reaction Reporting Syst | 2000 |